THE ORPHAN DRUG-ACT - IS IT A BARRIER TO INNOVATION - DOES IT CREATE UNINTENDED WINDFALLS

被引：0
|
作者：
KENNEY, PJ
机构：
来源：
FOOD AND DRUG LAW JOURNAL | 1988年 / 43卷 / 04期
关键词：
D O I：
暂无
中图分类号：
TS2 [食品工业];
学科分类号：
0832 ;
摘要：
引用
收藏
页码：667 / 679
页数：13
相关论文
共 29 条
  • [21] POSSIBLE AMENDMENTS TO ORPHAN DRUG-ACT - RETROACTIVITY AND SALES CAP WOULD-BE AVOIDED
    不详
    BIOTECHNOLOGY LAW REPORT, 1994, 13 (04): : 481 - 482
  • [22] GLYCOPROTEIN PHARMACEUTICALS - SCIENTIFIC AND REGULATORY CONSIDERATIONS, AND THE UNITED-STATES ORPHAN DRUG-ACT
    LIU, DTY
    TRENDS IN BIOTECHNOLOGY, 1992, 10 (04) : 114 - 120
  • [23] The Orphan Drug Act: An engine of innovation? At what cost?
    Rohde, DD
    FOOD AND DRUG LAW JOURNAL, 2000, 55 (01) : 125 - 143
  • [24] PRESCRIPTION FOR THE ORPHAN DRUG-ACT - THE IMPACT OF THE FDAS 1992 REGULATIONS AND THE LATEST CONGRESSIONAL PROPOSALS FOR REFORM
    CLISSOLD, DB
    FOOD AND DRUG LAW JOURNAL, 1995, 50 (01): : 125 - 147
  • [25] Progesterone for Prevention of Preterm Birth Shortcomings and Unintended Consequences of the Orphan Drug Act
    Gee, Rebekah E.
    Kuy, SreyRam
    Karas, Laura O.
    OBSTETRICS AND GYNECOLOGY, 2017, 130 (06): : 1202 - 1206
  • [26] Regulatory policy, value of knowledge assets and innovation strategy: The case of the Orphan Drug Act
    Rzakhanov, Zaur
    RESEARCH POLICY, 2008, 37 (04) : 673 - 689
  • [27] EDITORIAL BY CONCERNED PHYSICIANS: UNINTENDED EFFECT OF THE ORPHAN DRUG ACT ON THE POTENTIAL COST OF 3,4-DIAMINOPYRIDINE
    Burns, Ted M.
    Smith, Gordon A.
    Allen, Jeffrey A.
    Amato, Anthony A.
    Arnold, W. David
    Barohn, Richard
    Benatar, Michael
    Bird, Shawn J.
    Bromberg, Mark
    Chahin, Nizar
    Ciafaloni, Emma
    Cohen, Jeffrey A.
    Corse, Andrea
    Crum, Brian A.
    David, William S.
    Dimberg, Elliot
    De Sousa, Eduardo A.
    Donofrio, Peter D.
    Dyck, P. James B.
    Engel, Andrew G.
    Ensrud, Erik R.
    Ferrante, Mark
    Freimer, Miriam
    Gable, Karissa L.
    Gibson, Summer
    Gilchrist, James M.
    Goldstein, Jonathan M.
    Gooch, Clifton L.
    Goodman, Brent P.
    Gorelov, Dmitri
    Gospe, Sidney M., Jr.
    Goyal, Namita A.
    Guidon, Amanda C.
    Guptill, Jeffrey T.
    Gutmann, Laurie
    Gutmann, Ludwig
    Gwathmey, Kelly
    Harati, Yadollah
    Harper, C. Michel, Jr.
    Hehir, Michael K.
    Hobson-Webb, Lisa D.
    Howard, James F., Jr.
    Jackson, Carlayne E.
    Johnson, Nicholas
    Jones, Sarah M.
    Juel, Vern C.
    Kaminski, Henry J.
    Karam, Chafic
    Kennelly, Kathleen D.
    Khella, Sami
    MUSCLE & NERVE, 2016, 53 (02) : 165 - 168
  • [28] What Does the Food and Drug Administration Safety and Innovation Act Mean For You?
    Novack, Gary D.
    OCULAR SURFACE, 2013, 11 (03): : 206 - 209
  • [29] DOES A HIGHLY DILUTED HOMEOPATHIC DRUG-ACT AS A PLACEBO IN HEALTHY-VOLUNTEERS - EXPERIMENTAL-STUDY OF BELLADONNA-30C IN DOUBLE-BLIND CROSSOVER DESIGN - A PILOT-STUDY
    WALACH, H
    JOURNAL OF PSYCHOSOMATIC RESEARCH, 1993, 37 (08) : 851 - 860
123